| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 546216000 | Chalcogen bonded directly to ring carbon of the piperidine ring | 13 |
| 546217000 | Chalcogen and a carbocyclic ring bonded directly at 4-position | 3 |
| 20150376126 | METHOD FOR THE SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND NOVEL COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE - A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): | 12-31-2015 |
| 20160168092 | Process For The Preparation Of High Purity Miglustat | 06-16-2016 |
| 546218000 | The chalcogen, X, is part of a -C(=X)X- group, wherein the X's are the same or diverse chalcogens | 1 |
| 20110054178 | PROCESS FOR THE MANUFACTURE OF [PHENYLSULFANYLPHENYL]PIPERIDINES - A process for the manufacture of (un)substituted phenylsulfanylphenyl-piperidines comprising the use of benzyl as N-piperidine protecting group is disclosed. | 03-03-2011 |
| 546219000 | Plural chalcogens bonded directly to ring carbons of the piperidine ring | 1 |
| 546220000 | Having -C(=X)-, wherein X is chalcogen, attached directly or indirectly to the piperidine ring by nonionic bonding | 1 |
| 20090143592 | Glucagon Antagonists/Inverse Agonists - A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity. | 06-04-2009 |
| 546221000 | Having -C(=X)-, wherein X is chalogen, attached directly or indirectly to the piperidine ring by nonionic bonding | 9 |
| 20090137813 | PROCESS FOR PRODUCTION OF CAREBASTINE - Processes are disclosed for preparing piperidine derivative compounds of the formulae I, II or III: | 05-28-2009 |
| 20100280250 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS - A compound comprising a prodrug of a prostaglandin EP | 11-04-2010 |
| 20110065923 | PROCESS FOR PRODUCTION OF CAREBASTINE - Processes are disclosed for preparing piperidine derivative compounds of the formulae I, II or III: | 03-17-2011 |
| 20110295014 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES - The present invention discloses processes for preparing piperidine derivative compounds of the formulae: | 12-01-2011 |
| 20140235864 | BIPHENYL DERIVATIVES - This invention provides biphenyl derivatives of formula I: | 08-21-2014 |
| 20140309426 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX - The present invention features pharmaceutical compositions and methods of using pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction. | 10-16-2014 |
| 546222000 | The -C(=X)- group and the piperidine ring are bonded directly to the same chalcogen | 3 |
| 20090270629 | PROCESS FOR PREPARING QUATERNARY SALTS OF PIPERIDYL ESTERS OF MANDELIC ACID - What is described is a process for preparing compounds of the general formula (I) | 10-29-2009 |
| 20120046469 | Process for the Preparation of a Biphenyl-2-Yl carbamic Acid Ester - A novel process for the preparation of the compound of formula (II): | 02-23-2012 |
| 20150038719 | Agent for Ameliorating Chronic Obstructive Pulmonary Disease - This invention provides a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect. The agent for ameliorating chronic obstructive pulmonary disease contains mepenzolate bromide as an active ingredient. More preferably the mode of administration of the agent for ameliorating chronic obstructive pulmonary disease is airway administration or inhalation administration, and furthermore the mode of administration thereof is oral administration or rectal administration. This invention is a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect of mepenzolate bromide. | 02-05-2015 |
